Nat Commun:研究发现FDA批准的这种降压药还能延长寿命!

2017-12-22 sunshine2015 来宝网

UT西南医学中心的研究人员发现,FDA批准的用于治疗高血压的药物似乎通过可能模拟热量限制的细胞信号传导途径延长了蠕虫的寿命。

FDA批准的高血压药物延长了蛔虫的寿命】UT西南医学中心的研究人员发现,FDA批准的用于治疗高血压的药物似乎通过可能模拟热量限制的细胞信号传导途径延长了蠕虫的寿命。

药物肼苯哒嗪在两种秀丽隐杆线虫(蛔虫)中延长了约25%的寿命,一种是野生型,另一种则产生高水平的神经毒性蛋白,称为tau,在人中与阿尔茨海默病有关。

“这是肼苯哒嗪治疗激活NRF2 / SKN-1信号通路的第一个报道,我们发现这种药物延长了蠕虫的寿命,甚至比其他潜在的抗衰老化合物如姜黄素和二甲双胍还要好。通过测试灵活性和摆动速度来衡量,似乎能够保持健康。“UT Southwestern生物化学助理教授Hamid Mirzaei博士说。

NRF2途径保护人类细胞免受氧化应激。他说,人体保护自身免受破坏性氧自由基的能力随着年龄的增长而减少。

老年痴呆症和阿尔茨海默病和帕金森病等神经退行性疾病的标志之一是氧化应激,据认为这种氧化应激从整个生命过程中的炎症和感染性疾病累积而来,米尔扎伊博士解释说。线虫转录因子SKN-1对应于人类中的NRF2。他说,两者在各自物种对氧化应激和寿命的反应中起着举足轻重的作用。

UT Southwestern的研究人员正在寻找一种化学探针,他们可以在实验中使用这些化学探针来鉴定在衰老过程中被氧化并变得有毒的蛋白质。他们筛选的物质将穿越血脑屏障,无毒。

年龄相关的神经退行性疾病具有破坏性,由于人类寿命的延长,这些疾病正在增加。因此,开发治疗方法以尽可能保持健康是非常重要的。 Mirzaei也是AD西南大学的Peter O'Donnell Jr.脑研究所的成员,他是阿尔茨海默病和神经退行性疾病中心的研究员。

研究人员在体内(在一个有生命的生物)和在体外(在一个实验室盘)研究蠕虫,还研究了一种称为神经母细胞瘤的儿科癌症的人类细胞。与未经处理的对照相比,该药物治疗的蛔虫寿命(从15-18天增加到约20-23天)增加约25%。

他说,一系列生物化学实验的结果表明,肼苯哒嗪衍生的寿命延长依赖于蠕虫的SKN-1途径,通过似乎模拟热量限制的机制。

为了测试肼苯哒嗪在神经退行性疾病中的效力,科学家们使用高剂量的化学应激物质鱼藤酮,这种化学物质应激物与高剂量暴露于人类的帕金森病风险增加有关。他们发现肼苯哒嗪能提供相当数量的神经保护作用,Mirzaei博士说。他补充说,这种药物在阿尔茨海默氏病秀丽隐杆线虫模型中也表现出tau毒性的显着下降。

他说:“根据这些结果,我们认为肼苯哒嗪可能是治疗人类年龄相关疾病的临床试验的良好候选者,因为它也可能为老年人群提供一般健康益处。”他强调说,这项研究是有希望的第一步,但需要进一步的研究来证实。

原始出处:

Esmaeil Dehghan, Yiqiang Zhang, Bahar Saremi, et al. Hydralazine induces stress resistance and extends C. elegans lifespan by activating the NRF2/SKN-1 signalling pathway. Nature Communications 8, 2223.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087239, encodeId=54f7208e23911, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon May 14 04:33:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882724, encodeId=1c2c1882e24a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 26 10:33:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839563, encodeId=b21f1839563ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Oct 04 18:33:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753355, encodeId=bd3e1e5335547, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Sep 05 20:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291945, encodeId=d223129194549, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479859, encodeId=8a0b14e9859ff, content=<a href='/topic/show?id=456b4954350' target=_blank style='color:#2F92EE;'>#延长寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49543, encryptionId=456b4954350, topicName=延长寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9587588723, createdName=hittouch, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2018-05-14 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087239, encodeId=54f7208e23911, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon May 14 04:33:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882724, encodeId=1c2c1882e24a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 26 10:33:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839563, encodeId=b21f1839563ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Oct 04 18:33:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753355, encodeId=bd3e1e5335547, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Sep 05 20:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291945, encodeId=d223129194549, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479859, encodeId=8a0b14e9859ff, content=<a href='/topic/show?id=456b4954350' target=_blank style='color:#2F92EE;'>#延长寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49543, encryptionId=456b4954350, topicName=延长寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9587588723, createdName=hittouch, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2018-10-26 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087239, encodeId=54f7208e23911, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon May 14 04:33:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882724, encodeId=1c2c1882e24a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 26 10:33:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839563, encodeId=b21f1839563ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Oct 04 18:33:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753355, encodeId=bd3e1e5335547, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Sep 05 20:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291945, encodeId=d223129194549, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479859, encodeId=8a0b14e9859ff, content=<a href='/topic/show?id=456b4954350' target=_blank style='color:#2F92EE;'>#延长寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49543, encryptionId=456b4954350, topicName=延长寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9587588723, createdName=hittouch, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2018-10-04 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087239, encodeId=54f7208e23911, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon May 14 04:33:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882724, encodeId=1c2c1882e24a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 26 10:33:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839563, encodeId=b21f1839563ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Oct 04 18:33:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753355, encodeId=bd3e1e5335547, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Sep 05 20:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291945, encodeId=d223129194549, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479859, encodeId=8a0b14e9859ff, content=<a href='/topic/show?id=456b4954350' target=_blank style='color:#2F92EE;'>#延长寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49543, encryptionId=456b4954350, topicName=延长寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9587588723, createdName=hittouch, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087239, encodeId=54f7208e23911, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon May 14 04:33:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882724, encodeId=1c2c1882e24a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 26 10:33:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839563, encodeId=b21f1839563ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Oct 04 18:33:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753355, encodeId=bd3e1e5335547, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Sep 05 20:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291945, encodeId=d223129194549, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479859, encodeId=8a0b14e9859ff, content=<a href='/topic/show?id=456b4954350' target=_blank style='color:#2F92EE;'>#延长寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49543, encryptionId=456b4954350, topicName=延长寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9587588723, createdName=hittouch, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2087239, encodeId=54f7208e23911, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon May 14 04:33:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882724, encodeId=1c2c1882e24a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Oct 26 10:33:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839563, encodeId=b21f1839563ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Oct 04 18:33:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753355, encodeId=bd3e1e5335547, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Sep 05 20:33:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291945, encodeId=d223129194549, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479859, encodeId=8a0b14e9859ff, content=<a href='/topic/show?id=456b4954350' target=_blank style='color:#2F92EE;'>#延长寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49543, encryptionId=456b4954350, topicName=延长寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9587588723, createdName=hittouch, createdTime=Sun Dec 24 06:33:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]

相关资讯

不是降压药却能引起低血压的药物

体循环动脉血压是血液在血管中流动时对血管壁的压力,是血液流动的动力。血压是血液循环流动的前提,血压在多种因素调节下保持正常,从而提供各组织器官以足够的血量,以维持正常的新陈代谢。血压有极其重要的生物学意义,过低过高都会造成严重后果。提到降血压,一般会想到降压药,除常规的降压药物外,很多药物也具有一定的心血管活性,可降低血压,不合理使用或可导致低血压事件发生,下面对这些药物进行归纳总结,方便临床参考

Clin Exp Hypertens:如何选择降压药?单纯收缩压或舒张压高怎么办?

单药治疗高血压往往效果不好,需要几种降压药联合用药。还有很多老年人是单纯收缩压(高压)高,或者很多中青年单纯舒张压(低压)高,对此该如何选择降压药呢?

吃降压药有副作用,咋办?

1一些高血压患者服用降压药后可能会出现不适反应。遇到这种情况,一般不要自行停药,而是应该咨询医生,在医生指导下酌情处理。2这些不良反应有的是某种类型降压药所特有的副作用,也有的是血压降低所引起的。例如,一些平时血压很高但没有接受治疗的患者,服用降压药降低血压后可能会出现头晕、头痛、心慌、由坐位站起来时眼前发黑等。遇到这种情况一般不用停药,适当减小药物剂量后症状多可缓解。对于刚开始用药的患者,不要用

Circ Cardiovasc Qual Outcomes:3种非专利降压药商业化对不良事件有何影响?

当专利药品的专利保护到期时,非专利药品生产商就能够合法地制作同样配方的药品,并以更便宜的价格出售。但非专利药物与专利药品完全等效吗?不良事件的发生率又会如何呢?2017年10月,发表在《Circ Cardiovasc Qual Outcomes》的一项基于人群的时间序列分析调查了3种非专利血管紧张素II受体阻滞剂氯沙坦、缬沙坦和坎地沙坦的商业化对不良事件的影响。

六类降压药:作用特点、临床选择和注意事项,全在这里!

临床工作中,经常遇到患者提出这样的疑问:这么多降压药,我该怎么使用?不只是患者不知道怎么用,一些非专科医生也可能不知道降压药的合理使用。前一段时间,曾经在我科住院的一个老年患者春节后回来复查,自诉春节期间和春节后血压特别高,无论怎么都控制不住。这个老爷子不到70岁,高血压20余年,近两年血压维持在180 mmHg左右,稍一激动就到200 mmHg。去年因双下肢水肿、血肌酐升高住院治疗,诊断为高